Change search
ReferencesLink to record
Permanent link

Direct link
Effects of prostacyclin on the early inflammatory response in patients with traumatic brain injury-a randomised clinical study
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Anaesthesiology.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Clinical Microbiology, Infectious Diseases.
The Sahlgrenska Academy, University of Gothenburg.
Show others and affiliations
2014 (English)In: SpringerPlus, ISSN 2193-1801, Vol. 3, 98- p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE AND DESIGN: A prospective, randomised, double-blinded, clinical trial was performed at a level 1 trauma centre to determine if a prostacyclin analogue, epoprostenol (Flolan®), could attenuate systemic inflammatory response in patients with severe traumatic brain injury (TBI).

SUBJECTS: 46 patients with severe TBI, randomised to epoprostenol (n = 23) or placebo (n = 23).

TREATMENT: Epoprostenol, 0.5 ng · kg(-1) · min(-1), or placebo (saline) was given intravenously for 72 hours and then tapered off over the next 24 hours.

METHODS: Interleukin-6 (IL-6), interleukin-8 (IL-8), soluble intracellular adhesion molecule-1 (sICAM-1), C-reactive protein (CRP), and asymmetric dimethylarginine (ADMA) levels were measured over five days. Measurements were made at 24 h intervals ≤24 h after TBI to 97-120 h after TBI.

RESULTS: A significantly lower CRP level was detected in the epoprostenol group compared to the placebo group within 73-96 h (p = 0.04) and within 97-120 h (p = 0.008) after trauma. IL-6 within 73-96 h after TBI was significantly lower in the epoprostenol group compared to the placebo group (p = 0.04). ADMA was significantly increased within 49-72 h and remained elevated, but there was no effect of epoprostenol on ADMA levels. No significant differences between the epoprostenol and placebo groups were detected for IL-8 or sICAM-1.

CONCLUSIONS: Administration of the prostacyclin analogue epoprostenol significantly decreased CRP and, to some extent, IL-6 levels in patients with severe TBI compared to placebo. These findings indicate an interesting option for treatment of TBI and warrants future larger studies.

TRIAL REGISTRATION: Identifier, NCT01363583.

Place, publisher, year, edition, pages
Springer, 2014. Vol. 3, 98- p.
National Category
Anesthesiology and Intensive Care
URN: urn:nbn:se:umu:diva-88003DOI: 10.1186/2193-1801-3-98PubMedID: 24600548OAI: diva2:713075
Available from: 2014-04-18 Created: 2014-04-18 Last updated: 2014-04-23Bibliographically approved

Open Access in DiVA

fulltext(2123 kB)99 downloads
File information
File name FULLTEXT01.pdfFile size 2123 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wahlström, Marie RodlingOlivecrona, MagnusAhlm, ClasKoskinen, Lars-Owe DNaredi, SilvanaHultin, Magnus
By organisation
AnaesthesiologyClinical NeuroscienceInfectious Diseases
Anesthesiology and Intensive Care

Search outside of DiVA

GoogleGoogle Scholar
Total: 99 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link